Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Novel heparanase-inhibiting antibody reduces neointima formation.

Myler HA, Lipke EA, Rice EE, West JL.

J Biochem. 2006 Mar;139(3):339-45.

PMID:
16567398
3.

Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.

Zhao H, Liu H, Chen Y, Xin X, Li J, Hou Y, Zhang Z, Zhang X, Xie C, Geng M, Ding J.

Cancer Res. 2006 Sep 1;66(17):8779-87.

4.
5.

Factors controlling smooth-muscle cell proliferation.

Reidy MA.

Arch Pathol Lab Med. 1992 Dec;116(12):1276-80. Review.

PMID:
1456872
6.

Photodynamic therapy inactivates extracellular matrix-basic fibroblast growth factor: insights to its effect on the vascular wall.

LaMuraglia GM, Adili F, Karp SJ, Statius van Eps RG, Watkins MT.

J Vasc Surg. 1997 Aug;26(2):294-301.

7.

Role of basic fibroblast growth factor in vascular lesion formation.

Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA.

Circ Res. 1991 Jan;68(1):106-13.

10.

Imatinib mesilate inhibits neointimal hyperplasia via growth inhibition of vascular smooth muscle cells in a rat model of balloon injury.

Makiyama Y, Toba K, Kato K, Hirono S, Ozawa T, Saigawa T, Minagawa S, Isoda M, Asami F, Ikarashi N, Oda M, Moriyama M, Higashimura M, Kitajima T, Otaki K, Aizawa Y.

Tohoku J Exp Med. 2008 Aug;215(4):299-306.

11.

Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.

Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R, Vlodavsky I.

J Biol Chem. 2005 Apr 1;280(13):12103-13. Epub 2005 Jan 12.

12.

Photodynamic therapy mediated induction of accelerated re-endothelialisation following injury to the arterial wall: implications for the prevention of postinterventional restenosis.

Adili F, Scholz T, Hille M, Heckenkamp J, Barth S, Engert A, Schmitz-Rixen T.

Eur J Vasc Endovasc Surg. 2002 Aug;24(2):166-75.

13.

Suppression of neointimal lesions after vascular injury: a role for polyclonal anti-basic fibroblast growth factor antibody.

Nguyen HC, Steinberg BM, LeBoutillier M 3rd, Baumann FG, Rifkin DB, Grossi EA, Galloway AC.

Surgery. 1994 Aug;116(2):456-61; discussion 461-2.

PMID:
8048011
15.

Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.

Vlodavsky I, Ilan N, Naggi A, Casu B.

Curr Pharm Des. 2007;13(20):2057-73. Review.

PMID:
17627539
16.

Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models.

Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, Ilan N, Vlodavsky I, Abramovitch R.

FASEB J. 2005 Feb;19(2):211-21.

PMID:
15677344
17.

Screening and identification of novel B cell epitopes in human heparanase and their anti-invasion property for hepatocellular carcinoma.

Yang JM, Wang HJ, Du L, Han XM, Ye ZY, Fang Y, Tao HQ, Zhao ZS, Zhou YL.

Cancer Immunol Immunother. 2009 Sep;58(9):1387-96. doi: 10.1007/s00262-008-0651-x. Epub 2009 Jan 25.

PMID:
19169879
18.

Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease.

Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA.

Nephrology (Carlton). 2005 Apr;10(2):167-73.

PMID:
15877677
19.
20.

Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation.

Moura R, Tjwa M, Vandervoort P, Cludts K, Hoylaerts MF.

Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2163-9. Epub 2007 Aug 30.

Supplemental Content

Support Center